Lifecome Biochemistry Co.,Ltd.

Shenzhen Stock Exchange 002868.SZ

Lifecome Biochemistry Co.,Ltd. EBITDA Margin for the year ending December 31, 2023: -25.23%

Lifecome Biochemistry Co.,Ltd. EBITDA Margin is -25.23% for the year ending December 31, 2023, a -54.93% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Lifecome Biochemistry Co.,Ltd. EBITDA Margin for the year ending December 31, 2022 was -16.29%, a -567.82% change year over year.
Lifecome Biochemistry Co.,Ltd. EBITDA Margin for the year ending December 31, 2021 was 3.48%, a -86.57% change year over year.
Lifecome Biochemistry Co.,Ltd. EBITDA Margin for the year ending December 31, 2020 was 25.92%, a -17.77% change year over year.
Lifecome Biochemistry Co.,Ltd. EBITDA Margin for the year ending December 31, 2019 was 31.52%, a 18.30% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shenzhen Stock Exchange: 002868.SZ

Lifecome Biochemistry Co.,Ltd.

CEO	Mr. Zhongshou Bao
IPO Date	May 3, 2017
Location	China
Headquarters	No. 19,Nanpu Ecological Industrial Park
Employees	992
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Cosmetics Fertilizers Pet Food Pharmaceuticals Plastics

Description

Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. The company was founded in 2003 and is based in Pucheng, China.

Key trends

Past 5 years